Introduction
============

Medullary thyroid carcinoma (MTC) is a rare malignancy arising from calcitonin-producing parafollicular C cells of the thyroid gland \[[@mdx479-B1], [@mdx479-B2]\]. MTC accounts for ∼2% of all thyroid carcinomas and up to 14% of thyroid cancer--related deaths. About half of patients with MTC present with lymph node metastases and 10% with distant metastatic disease \[[@mdx479-B3]\]. Survival rates vary according to disease stage \[[@mdx479-B3]\]. The 10-year survival rate is 96% for patients with tumors confined to the thyroid gland but only 40% for those with distant metastases \[[@mdx479-B2]\].

Approximately 75% of cases of MTC occur sporadically, whereas 25% are associated with one of two inherited autosomal dominant syndromes---multiple endocrine neoplasia 2 A (MEN2A) or MEN2B \[[@mdx479-B3], [@mdx479-B4]\]. A number of mutations and signaling pathways have been implicated in MTC pathogenesis. Nearly all patients with hereditary forms have germline mutations identified in the gene encoding the RET protein \[[@mdx479-B5]\], and somatic *RET* mutations have been reported in up to 65% of patients with sporadic disease \[[@mdx479-B6]\]. About half of all somatic *RET* mutations are the M918T point mutation, which is associated with poor prognosis \[[@mdx479-B8], [@mdx479-B9]\]. In patients with sporadic MTC lacking *RET* mutations, *RAS* gene mutations are common, occurring in up to 68% of cases \[[@mdx479-B7], [@mdx479-B10], [@mdx479-B11]\]. In addition, the vascular endothelial growth factor and MET pathways are thought to promote angiogenesis, invasion, and metastasis in MTC \[[@mdx479-B3], [@mdx479-B12], [@mdx479-B13]\].

Chemotherapy has limited activity in patients with unresectable or metastatic MTC \[[@mdx479-B3]\]. More recently, multitargeted kinase inhibitors (MKIs) have been approved for locally advanced or metastatic MTC \[[@mdx479-B6], [@mdx479-B14]\].

Cabozantinib, an inhibitor of kinases, including MET, vascular endothelial growth factor receptors, and RET \[[@mdx479-B15]\], is approved in the United States and Europe for progressive, metastatic MTC based on findings of the EXAM trial (Trial Registration Number: NCT00704730) \[[@mdx479-B14]\]. In this phase III study, cabozantinib significantly prolonged progression-free survival (PFS), the primary end point, compared with placebo in patients with documented radiographic progression of metastatic MTC (estimated median PFS 11.2 versus 4.0 months; hazard ratio \[HR\], 0.28; 95% confidence interval \[CI\], 0.19--0.40; *P *\< 0.001) \[[@mdx479-B14]\]. At the primary analysis, a planned interim analysis of OS showed no difference between treatment arms (HR, 0.98; 95% CI, 0.63--1.52), but only 96 of the planned 217 deaths for the final analysis had occurred.

We report here the final OS analysis for the EXAM trial after additional follow-up and include updated safety data after long-term treatment with cabozantinib.

Patients and methods
====================

Study design and patients
-------------------------

The EXAM study design has been described previously \[[@mdx479-B14]\]. In brief, EXAM was an international, double-blind, randomized, placebo-controlled phase III study evaluating cabozantinib in adult patients with unresectable locally advanced or metastatic MTC. Patients were required to have documented radiographic disease progression per Response Evaluation Criteria in Solid Tumors guidelines version 1.0 at screening compared with images obtained within the prior 14 months. No limit was placed on number of prior therapies, including MKIs. All patients provided written informed consent. The protocol was approved by ethics committees or institutional boards at each clinical site, nationally, or both.

The primary end point was PFS \[[@mdx479-B14]\]. Key secondary end points were objective response rate (ORR), OS, and assessment of the relationship between *RET* mutation status and efficacy of cabozantinib \[[@mdx479-B14]\]. Mutations in the *RET* gene (exons 10, 11, and 13--16) were identified from blood and archival tumor samples using Sanger and next-generation sequencing methods \[[@mdx479-B14], [@mdx479-B16]\], and a subset of tumor samples not harboring *RET* mutations was also analyzed for mutations in *HRAS*, *KRAS*, and *NRAS* at codons 12, 13, and 61 \[[@mdx479-B14], [@mdx479-B16]\].

Randomization and treatment
---------------------------

Patients were randomized to receive cabozantinib or placebo (2:1) stratified by age (≤65 and \>65 years) and prior MKI treatment (yes, no) \[[@mdx479-B14]\]. Patients received cabozantinib (140 mg/day) or placebo administered orally until intolerable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors version 1.0. The study was unblinded after the primary analysis of PFS. Patients receiving placebo were not allowed to crossover to cabozantinib.

Overall survival analysis
-------------------------

An interim OS analysis was planned at the time of the primary PFS analysis. The final OS analysis was to be conducted after at least 217 deaths were observed in the intent-to-treat population. This provided 80% power to detect an HR of 0.667 using the log-rank test and a 2-sided significance level of 4% (allocated at interim and final analyses per an alpha spending function), corresponding to a 33.3% reduction in rate of death or a 50% increase in median survival from 22 to 33 months.

Median OS was estimated using the Kaplan--Meier method. For patients who were alive at the time of data cutoff for the current analysis (28 August 2014) or who were lost to follow-up, the duration of OS was right censored at the date the patient was last known to be alive. Testing between the two treatment arms was carried out by the stratified log-rank test using randomization stratification factors. The HR was estimated using a Cox regression model with treatment group as the main effect and included the randomization stratification factors. In an exploratory subgroup analysis, we assessed OS and PFS by baseline demographics and characteristics, and *RET* and *RAS* mutation status. Analyses on the basis of *RET* mutation status were pre-specified (*RET* mutation--positive, *RET* mutation--negative, and *RET* mutation--unknown subgroups), while analyses based on *RAS* mutation status or the presence of the *RET* M918T mutation were post hoc. The primary analysis data cut-off of 6 April 2011 was used for all PFS analyses. Calculated *P* values for subgroups are descriptive only.

Safety analysis
---------------

Safety assessments included evaluation of adverse events (AEs), serious AEs (SAEs), deaths, standard laboratory tests, physical examinations, and electrocardiograms. Severity of AEs was based on National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3. SAEs were defined in accordance with International Conference on Harmonisation Guidelines for Clinical Safety Data Management (1994).

Results
=======

Patients
--------

At data cut-off (28 August 2014), 10% (21/219) of patients in the cabozantinib group were still receiving treatment; all patients in the placebo group had discontinued ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Detailed baseline characteristics of the randomized patients were balanced between arms \[[@mdx479-B14]\]. Briefly, 40% of all patients (*n* = 133) had received prior anticancer therapy, and 21% (*n* = 68) prior MKI treatment. One quarter (25%) of patients (n = 83) had received ≥2 systemic therapies. The main sites of metastases were lymph nodes, liver, lung, and bone. *RET* and *RAS* mutational status are summarized in [supplementary Table S1](#sup3){ref-type="supplementary-material"}, available at *Annals of Oncology* online. Apart from mutational status, *RET* subgroups showed similar baseline characteristics ([supplementary Table S2](#sup4){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

OS and PFS
----------

In this OS analysis, 64% (141/219) of patients in the cabozantinib arm and 69% (77/111) in the placebo arm had died. Minimum follow-up was 42 months. There was a 5.5-month numerical increase in median OS with cabozantinib versus placebo (26.6 versus 21.1 months). However, this difference did not reach statistical significance (stratified HR, 0.85; 95% CI, 0.64--1.12; *P *=* *0.24) (Figure [1](#mdx479-F1){ref-type="fig"}A).

![Kaplan--Meier curve of overall survival (OS) and progression-free survival (PFS) in the (A) overall intent-to-treat population, (B) in patients with *RET* M918T--positive disease, and (C) in patients with *RET* M918T--negative disease. Data cut-off was 28 August 2014 for OS and 6 April 2011 for PFS. ^a^Analyses for (A) were stratified by randomization stratification factors, and analyses of subgroups (B and C) were unstratified. HR, hazard ratio; CI, confidence interval. *P* values were not adjusted for multiple comparisons. Methods for determining *RET* M918T status are described elsewhere \[[@mdx479-B16]\].](mdx479f1){#mdx479-F1}

![Subgroup analysis of overall survival and progression-free survival (PFS) according to *RET* mutation status, *RET* M918T status, and *RAS* mutations status. Data cut-off was 28 August 2014 for overall survival and 6 April 2011 for PFS. ^a^Analyses for all patients were stratified by randomization stratification factors, and analyses of subgroups were unstratified. HR, hazard ratio; CI, confidence interval. Methods for determining *RET* and *RAS* mutation status are described elsewhere \[[@mdx479-B16]\].](mdx479f2){#mdx479-F2}

OS and PFS data were assessed in subgroups, including *RET* mutation status, *RET* M918T mutation status, and *RAS* mutation status (Figures [1](#mdx479-F1){ref-type="fig"}B and C and [2](#mdx479-F2){ref-type="fig"}), as well as demographics and baseline characteristics ([supplementary Figure S2](#sup4){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Cabozantinib was favored over placebo for both OS and PFS in patients with and without *RET* mutations and for those with an unknown *RET* mutation status. There was a substantial OS benefit associated with cabozantinib in the *RET* M918T--positive subgroup with a median OS of 44.3 versus 18.9 months for placebo \[HR, 0.60; 95% CI, 0.38--0.94; *P *=* *0.03 (not adjusted for multiple subgroup analyses)\]. PFS in the *RET* M918T--positive subgroup were consistent with OS, favoring cabozantinib (HR, 0.15; 95% CI 0.08--0.28; *P* \<0.0001). For the *RET* M918T--negative subgroup, there was no OS benefit with cabozantinib (HR, 1.12; 95% CI, 0.70--1.82; *P *=* *0.63), whereas there was a trend toward improved PFS that did not reach statistical significance (HR, 0.67; 95% CI, 0.37--1.23; *P *=* *0.19). At the time of the primary analysis (cut-off of 6 April 2011), the ORR for patients receiving cabozantinib was 28% overall, 34% for the *RET* M918T--positive subgroup, and 20% for the *RET* M918T--negative subgroup. There were no responses in the placebo arm.

Subgroup analysis of patients harboring *RAS* mutations showed a trend toward improved OS (HR, 0.37; 95% CI, 0.10--1.42) and PFS (HR, 0.15; 95% CI, 0.02--1.10). However, this was a small subgroup (13 patients in the cabozantinib arm and three in the placebo arm) and differences between arms were not statistically significant.

Subsequent anticancer therapy
-----------------------------

The percentage of patients who received any subsequent anticancer therapy was 44% (32% systemic therapy) in the cabozantinib group and 58% (50% systemic therapy) in the placebo group ([supplementary Table S3](#sup5){ref-type="supplementary-material"}, available at *Annals of Oncology* online). MKIs were frequently used as subsequent systemic therapy (27% in the cabozantinib group, 41% in the placebo group). For patients receiving subsequent therapy, there was no OS benefit with cabozantinib versus placebo (HR, 0.93; 95% CI, 0.63--1.39), while cabozantinib was favored in patients who did not receive subsequent therapy (HR, 0.59; 95% CI, 0.39--0.88) ([supplementary Figure S2](#sup2){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

Safety
------

Median duration of exposure to cabozantinib was 10.8 months (interquartile range, 3.3--25.1 months) with 25% receiving cabozantinib for \>2 years. This was more than three times that of the placebo arm (median 3.4 months; interquartile range, 3.0--6.5 months). The proportion of cabozantinib-treated patients who had a dose reduction was 82%, and 46% underwent a second-level dose reduction.

Safety data have been updated through the 28 August 2014 cut-off. AEs reported in** **≥20% of patients are summarized in Table [1](#mdx479-T1){ref-type="table"} ([supplementary Table S4](#sup6){ref-type="supplementary-material"}, available at *Annals of Oncology* online for AEs reported in** **≥10%). The types and rates of AEs in this updated analysis remained consistent with the PFS analysis \[[@mdx479-B14]\]. The most frequently reported SAEs (≥2%) in the cabozantinib arm were pneumonia (4.2% versus 3.7% in the placebo arm), pulmonary embolism (3.3% versus 0%), hypocalcemia (2.8% versus 0%), mucosal inflammation (2.8% versus 0%), dehydration (2.3% versus 0.9%), dysphagia (2.3% versus 1.8%), hypertension (2.3% versus 0%), and lung abscess (2.3% versus 0%). Table 1.Adverse events occurring in ≥20% of cabozantinib-treated patients regardless of causality by maximum severity reportingCabozantinibPlacebo*N* = 214*N* = 109Grade, *n* (%)Grade, *n* (%)All≥3All≥3Diarrhea150 (70.1)46 (21.5)39 (35.8)2 (1.8)Weight decreased124 (57.9)21 (9.8)12 (11.0)0Palmar-plantar erythrodysesthesia syndrome113 (52.8)27 (12.6)2 (1.8)0Decreased appetite105 (49.1)15 (7.0)17 (15.6)1 (0.9)Nausea100 (46.7)4 (1.9)23 (21.1)0Fatigue91 (42.5)21 (9.8)33 (30.3)3 (2.8)Dysgeusia75 (35.0)1 (0.5)6 (5.5)0Hair color changes73 (34.1)1 (0.5)1 (0.9)0Hypertension70 (32.7)19 (8.9)5 (4.6)0Stomatitis64 (29.9)5 (2.3)3 (2.8)0Constipation60 (28.0)06 (5.5)0Vomiting56 (26.2)5 (2.3)2 (1.8)1 (0.9)Mucosal inflammation54 (25.2)7 (3.3)4 (3.7)0Asthenia53 (24.8)14 (6.5)16 (14.7)2 (1.8)Alanine aminotransferase increased52 (24.3)11 (5.1)6 (5.5)2 (1.8)Aspartate aminotransferase increased51 (23.8)4 (1.9)6 (5.5)0Hypocalcemia51 (23.8)23 (10.7)5 (4.6)0Rash49 (22.9)2 (0.9)11 (10.1)0Back pain47 (22.0)9 (4.2)16 (14.7)1 (0.9)Dysphonia47 (22.0)011 (10.1)0Abdominal pain47 (22.0)7 (3.3)8 (7.3)1 (0.9)Pain in extremity45 (21.0)4 (1.9)13 (11.9)1 (0.9)Dry skin43 (20.1)03 (2.8)0

Grade 5 AEs that occurred before the 15 June 2011 data cut-off were reported in the primary analysis \[[@mdx479-B14]\]. During the additional follow-up, six patients in the cabozantinib arm died while on study treatment or within 30 days of the last dose. One of these was considered related to study treatment (esophageal bleeding for a patient on treatment for 381 days). The other grade 5 AEs were considered unrelated to treatment and included multiorgan failure (one patient on treatment for 542 days), bronchopneumonia (one patient on treatment for 705 days), general physical health deterioration (two patients on treatment for 674 and 1324 days), and respiratory failure (one patient on treatment for 785 days).

Discussion
==========

In this updated analysis of the phase III EXAM trial in patients with progressive, metastatic MTC, the secondary end point of improved OS was not reached. Median OS was 5.5 months longer with cabozantinib versus placebo, but this did not achieve statistical significance. In exploratory analyses of OS, PFS, and ORR, cabozantinib appeared to be more active in patients who were *RET* M918T positive than in those who were *RET* M918T negative. For *RET* M918T--positive patients, median OS was 44.3 months for cabozantinib versus 18.9 months for placebo.

In the primary analysis of this trial, the primary end point of improved PFS was met. Median PFS with cabozantinib was 11.2 months compared with 4.0 months for placebo (HR, 0.28; 95% CI, 0.19--0.40; *P* \<0.001) \[[@mdx479-B14]\]. *RET* M918T--positive patients had longer PFS and higher ORR versus *RET* M918T--negative patients. OS results appear to be consistent with PFS but are limited because of the sample size. The trial was designed with reasonable power (80%) for OS as a secondary end point provided that cabozantinib treatment resulted in a large benefit (50% increase) based on study size. Because MTC is relatively rare, the feasibility of designing a trial assuming a more modest but clinically relevant OS benefit is not practical. In addition, the use of subsequent systemic anticancer therapy (38% of patients in the cabozantinib arm versus 50% of patients in the placebo arm) may also have impacted the OS results.

The OS findings in patients harboring an *RET* M918T mutation are of clinical interest although these are exploratory data. *RET* M918T has been associated with poorer prognosis for patients with sporadic disease and the most rapid course of disease development for patients with hereditary disease \[[@mdx479-B8], [@mdx479-B9]\]. The mechanisms by which patients with *RET* M918T--positive tumors would respond better to cabozantinib than those with *RET* M918T--negative tumors have not been characterized. However, cabozantinib's mechanism of action and the biochemical impact of the *RET* M918T mutation provide insight into the potential etiology. Possible contributing factors include the effects of the mutation of *RET* signaling, and its sensitivity to inhibition by cabozantinib. The M918T mutation in the *RET* kinase domain has been shown to increase its catalytic activity \[[@mdx479-B17]\]. Differences in downstream signaling between *RET* M918T and other *RET* isoforms have also been noted \[[@mdx479-B18], [@mdx479-B19]\], including enhanced activation of the RAS signaling pathway. The high catalytic activity of the M918T isoform and its strong ability to activate signaling in crucial downstream pathways may promote higher 'oncogene addiction' to *RET* and greater sensitivity to *RET* inhibition \[[@mdx479-B20]\]. Cabozantinib is a potent inhibitor of *RET*, including the wild-type and M918T isoforms \[[@mdx479-B21]\].

In contrast to the cabozantinib arm, the difference in OS between *RET* M918T--positive and *RET* M918T--negative patients who were randomized to the placebo arm was less notable (\<3 months) despite previously reported association of *RET* M918T with poor prognosis \[[@mdx479-B8], [@mdx479-B9]\]. This may be attributable to all patients in the EXAM study having advanced progressive disease at study entry.

The results of this current analysis suggest that identification of tumors bearing somatic *RET* M918T mutations may be a predictive biomarker for progressive MTC, but this will require confirmation and validation. Further, determination of *RET* mutational status in the clinical setting presents challenges. There are technical limitations to sequencing, and mutations may be present in only some lesions or at later disease stages \[[@mdx479-B22]\]. Given these caveats and the activity of cabozantinib in the *RET* M918T--negative group with respect to PFS and ORR, patients with progressive MTC should not be excluded from cabozantinib treatment based solely on tumor genotype.

There were no new or unexpected signals in the updated safety data for patients treated with cabozantinib, some of whom remained on treatment for extended periods---25% of patients received cabozantinib for \>2 years \[[@mdx479-B14]\]. The majority of patients underwent dose reductions, suggesting that with appropriate dose reductions and AE management, patients can maintain long-term treatment with cabozantinib. The study of cabozantinib in MTC is continuing, including a trial comparing the 140-mg starting dose in capsules to a 60-mg starting dose in tablets (ClinicalTrials.gov NCT01896479). This study will also evaluate the relationship of *RET* M918T status with clinical activity.

In conclusion, in this final analysis of OS from the EXAM trial, the secondary end point of OS was not met. A statistically non-significant increase in OS of 5.5 months was observed for cabozantinib compared with placebo in patients with metastatic MTC with documented radiographic progression. Among subgroups, the largest OS benefit was observed in *RET* M918T--positive patients. After extended treatment, the cabozantinib safety profile remained consistent with that reported in the primary analysis.
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